# AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections

> **NIH NIH UM1** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 · $44,503,132

## Abstract

Project Summary
The AIDS Clinical Trials Group (ACTG) has been at the forefront of clinical research to advance HIV
therapeutics and improve the health of people living with HIV/AIDS for 30 years. Rigorous scientific research
conducted by the ACTG has laid the cornerstones for current HIV treatment guidelines. In this application for
the competitive renewal of the ACTG we propose a transformative research agenda that draws on an
international consortium of leading clinical and laboratory HIV investigators in collaboration with a world-class
Statistics and Data Management Center to design and conduct innovative interventional clinical trials that will
significantly reduce the global burden of disease due to HIV, TB and hepatitis B.
The Leadership and Operations Center (LOC) provides scientific leadership and fiscal and organizational
management of the ACTG. The ACTG Executive Committee (AEC) will serve as the overarching governing
body of the network. The AEC is guided by an Executive Management Committee that includes the Network
Chairs, Chief Quality Officer and the Chairs of the Laboratory and Statistical and Data Management Centers.
Transformative Science Groups will oversee the development and execution of the ACTG research agenda,
which will be coordinated and prioritized by the Scientific Agenda Steering Committee (SASC). Protocol
development, implementation, training and network evaluation will be facilitated by the Network Clinical Core at
Social & Scientific Systems, Inc. The LOC financial management group (Admin Core) at the University of
California, Los Angeles will oversee resource management and protocol fund distribution at the direction of the
AEC. The LOC will assure the engagement of Community in all aspects of the ACTG, and will coordinate
communication between all three components of the network. Specific aims of this proposal include: 1) Identify
interventions to reduce HIV reservoirs and control HIV replication in the absence of ART; 2) Test novel and
durable interventions targeting HIV infection; 3) Improve the treatment and prevention of drug sensitive and drug
resistant tuberculosis; 4) Prevent or improve the treatment of HIV-related non-infectious co-morbidities and
evaluate strategies to cure hepatitis B virus infection in people with and without HIV.

## Key facts

- **NIH application ID:** 9983408
- **Project number:** 2UM1AI068636-15
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Judith S. Currier
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $44,503,132
- **Award type:** 2
- **Project period:** 2006-06-29 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9983408

## Citation

> US National Institutes of Health, RePORTER application 9983408, AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections (2UM1AI068636-15). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9983408. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*